



Case report

Ocular proptosis as a manifestation of Wegener's granulomatosis: Case report and literature review[☆]



Mauricio Zea Durán^a, María Alejandra Martínez-Ceballos^{b,c,*}

^a Departamento de Oftalmología, Fundación Cardioinfantil, Bogotá, Colombia

^b Facultad de Medicina, Universidad de La Sabana, Chía-Cundinamarca, Colombia

^c Programa de Medicina, Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia

ARTICLE INFO

Article history:

Received 17 July 2018

Accepted 21 February 2019

Available online 8 June 2020

ABSTRACT

Granulomatosis with polyangiitis (Wegener) is considered as a systemic, non-infectious granulomatous disease, histologically noted for its small vessel necrotizing vasculitis. The upper and lower respiratory tracts are the most frequently affected, in association with renal manifestations. However, the isolated involvement of a single organ, such as the eyeball and the orbit are also described. The case is presented of a woman whose main manifestation was an inflammatory process of periorbital tissue and proptosis of the left eyeball. The patient was evaluated jointly with eye plastic surgery, and the ear, nose and throat, and rheumatology departments.

A literature review was carried out, looking for case reports and case series that allowed comparisons to be made between the clinical manifestations and the most frequent outcomes.

© 2019 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

Proptosis ocular como una manifestación de la granulomatosis con poliangeítis (Wegener): Reporte de un caso y revisión de la literatura

RESUME

La granulomatosis con poliangeítis (Wegener) es considerada como una enfermedad granulomatosa sistémica, no infecciosa, caracterizada histológicamente por una vasculitis necrosante de pequeño vaso. El tracto respiratorio superior e inferior son los más frecuentemente afectados, en asociación a manifestaciones renales. Sin embargo, también se describe el compromiso aislado de un solo órgano, como es el caso del globo ocular y la órbita. Presentamos el caso de una mujer cuya principal manifestación consistió en un proceso inflamatorio de tejido periorbitario y proptosis del globo ocular izquierdo. La paciente

Palabras clave:

Enfermedad de órbita

Seudotumor orbitario

Proptosis

Vasculitis sistémica

Granulomatosis con poliangeítis

PII of original article: S0121-8123(19)30043-X

* Please cite this article as: Zea Durán M, Martínez-Ceballos MA. Proptosis ocular como una manifestación de la granulomatosis con poliangeítis (Wegener): Reporte de un caso y revisión de la literatura. Rev Colomb Reumatól. 2020;27:123–129.

* Corresponding author.

E-mail address: mariamace9@gmail.com (M.A. Martínez-Ceballos).

2444-4405/© 2019 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

fue valorada en manejo conjunto con el servicio de plástica ocular, otorrinolaringología y finalmente se derivó a reumatología para inicio de terapia inmunosupresora.

Se realizó una revisión de la literatura, en búsqueda de reportes de caso y series de caso que permitieran comparar las presentaciones clínicas y desenlaces más frecuentes.

© 2019 Asociación Colombiana de Reumatología. Publicado por Elsevier España, S.L.U.
Todos los derechos reservados.

Introduction

Granulomatosis with polyangiitis (GPA)^{1,2} is a systemic, non-infectious granulomatous disease, histologically characterized by small vessel necrotizing vasculitis.³ The upper and lower respiratory tracts are the most frequently affected and usually it is associated with pauci-immune glomerulonephritis.⁴ Among the isolated manifestations over the course of the disease, 52% of the patients with GPA present ocular manifestations,⁵ primarily necrotizing nodular episcleritis, scleritis and corneal ulcerations.⁴ Recent reviews estimate that the orbital involvement is more frequent than expected,⁶ which becomes a serious challenge due to impaired eyesight secondary to optic nerve compression, if it is not timely detected and managed.

There are a few cases of the disease reported in Colombia; however, there are yet no official figures regarding the incidence and prevalence of orbital pseudotumor secondary to this systemic disease. Moreover, the Latin American literature is quite sparse in terms of the isolated orbital involvement as the initial manifestation.

Following is a discussion of a case of a female patient with proptosis who was treated in several occasions as preseptal cellulitis, neglecting the clinical history that could have guided the practitioner toward an accurate diagnosis, and turned it into a multidisciplinary challenge.

Clinical case

54-Year old female patient original from Bogotá. History of weekly alcohol abuse since she was 15 years old until she became intoxicated. She smoked half a pack of cigarettes per day also since she was 15. The patient presented with upper respiratory symptoms in December 2016, due to nasal congestion, purulent post-nasal drip, epistaxis on one occasion and frontal headache, associated with erythema and left eyeball edema, leading to a diagnosis of maxillary sinus sinusitis and periorbital cellulitis. These episodes (approximately 8) experienced periods of improvement, with partial response until February 2017.

The patient received several cycles of broad-spectrum antibiotics, including metronidazole, clindamycin, ciprofloxacin, amoxicillin piperacillin/tazobactam and vancomycin.

In August 2017 she comes to the clinic with a 6-month proptosis, and is assessed by ENT and the decision was made to perform canthopexy, maxillary antrostomy and anterior ethmoidectomy. A biopsy is collected from the mucosa

which reported an acute and chronic inflammatory process with granulation tissue, soft tissues with abundant foamy histiocytes; the special stains failed to identify any microorganisms. An extra-institutional culture and hemoculture was performed prior to administering the antibiotic and it came out negative for microorganisms. However, based on the clinic, antibiotic therapy was initiated with cefepime for 7 days, leading to hospital at home care.

The doctors advised to refer the patient to ophthalmology due to the suspicion of orbital pseudotumor versus infiltrative process of the lacrimal gland. In view of the delay to authorize the patient's referral for assessment, the patient comes to the emergency department of our institution in October 2017, because she was experiencing photophobia, diplopia, reduced visual acuity, severe left ocular proptosis, blepharoptosis, associated with subjective vertigo and hearing loss.

The ophthalmological examination revealed a 20/20 right eye visual acuity; left eye: 20/40, edema and periorbital induration more predominant in the upper lid, and restricted lateral eye movements (Fig. 1). The biomicroscopy resulted in preserved pupillary reflexes, healthy anterior segment of the right eye, left eye with 2 mm lagophthalmos, hyperemic conjunctiva and chemosis, mucopurulent secretion, intraocular pressure and eye fundus within the normal limits.

A face CT-scan was ordered which showed as the primary diagnostic probability an orbital pseudotumor, lymphoproliferative disease or chronic mycotic process (Fig. 2). Joint management with ENT was advised and the ENT specialists prescribed audiometry which documented left ear neurosensorial hearing loss. A nuclear magnetic resonance of the cerebellopontine angle was indicated, which showed absence of lesions, presence of otomastoiditis and left maxillary sinusitis. The blood chemistry panel (Table 1) was normal and urinary sediment reporting isolated microhematuria, probably associated with asymptomatic bacteriuria.

The patient was discharged since this was a chronic process with no systemic involvement and was scheduled for ambulatory biopsy and establish the diagnosis of pseudotumor versus a malignant process.

The patient was readmitted to the ED due to persistent ophthalmological symptoms and with the histopathology results. The new report submits negative stains for microorganisms, evidence of chronic and acute inflammatory infiltrate, granulomatous reaction with giant cells and the presence of vasculitis in the arterioles and venules (Fig. 3). An interconsultation with internal medicine and rheumatology asked for further studies (Table 1), chest X-ray with no pulmonary involvement. A diagnosis of GPA was finally concluded due to the findings in the biopsy and the clinic. Methylprednisolone IV pulses 500 mg/day, were prescribed for 3 days following par-

Table 1 – Laboratory results.

Variable	October 2017	November 2017	February 2018	July 2018
CBC				
White blood cells count (10^3 cel/u)	8,830	9,410	10,900	14,200
Hemoglobin (g/dL)	14.9	14.30	15.50	15.8
Hematocrit (%)	43.40	45	46.10	49
Platelets (10^3 cel/u)	355,000	487,000	447,000	397,000
Neutrophils (10^3 cel/u)	4,630	3,810	5,600	9,150
Renal function				
Serum creatinine (mg/dL)	0.7	0.8	0.8	0.8
BUN (mg/dL)	16	17		
Acute phase reactants				
C-reactive protein (mg/dL)	5.24		1.81	1.21
Erythrocyte sedimentation rate (mm/h)	45	45	25	10
Clotting times				
Prothrombin time (PT) (s)	15.70	14.40		
PT control (s)	14.80	15.10		
INR	1.06	0.95		
Partial thromboplastin time (PTT) (s)	27.50	26.90		
PTT control (s)	29.90	29.90		
Blood chemistry panel				
Serum amylase (U/l)	59			
Alkaline phosphatase (U/l)	117		102	
Gama glutamyl transferase (U/l)	26			
Glutamic pyruvic transaminase (U/l)	30		46	
Glutamic oxaloacetic transaminase (U/l)	24		23	43
Total bilirubin (mg/dL)	0.5			
Direct bilirubin (mg/dL)	0.2			
Indirect bilirubin (mg/dL)	0.3			
Calcium (mg/dL)	10.1			
Chloride (mEq/l)	104			
Potassium (mEq/l)	4.1			
Sodium (mEq/l)	138			
Serology tests				
ANA	Negative			Negative
P-ANCA	Negative			
C-ANCA	Negative			
Myeloperoxidase antibodies (MPO) (U)				0.9
Serine proteinase-3 antibodies (PR3-3) (U)				2.1
Urinalysis				
Density	1.011	1.025		1.02
pH	5.5	6.5		6
Leukocytes (leuk/ μ l)	75	Negative		Negative
Nitrites	Negative	Negative		Negative
Proteins	Negative	Negative		Negative
Glucose	Negative	Negative		Negative
Ketone	Normal	Normal		Normal
Urobilinogen	Normal	Normal		Normal
Bilirubin	Negative	Negative		Negative
Blood (erythrocytes/ μ l)	50	Negative		Negative
Sediment				
Leukocytes (XC)	36.52	0–5		0–5
Erythrocytes (XC)	3.52	Negative		Negative
Epithelial squamous cells (XC)	33.00			
Epithelial non-squamous cells (XC)	0.44	11–20		0–5
Bacteria	+	+		Sparse
Microalbuminuria (mg/L)		30		10
Urine creatinine (mg/dL)		100		50




Fig. 1 – The left eye has a significant proptosis and blepharoptosis, with a space-occupying lesion in the upper half of the left orbit, conjunctival hyperaemia, conjunctivochalasis, mucoseroous secretion.




Fig. 2 – CT-scan of the face: (A) the left maxillary sinus is completely occupied, with soft tissue density associated with thickening of the adjacent bone cortex, relating to chronic inflammatory changes. (B and C) Diffuse alteration of the left periorbital soft tissues, with heterogeneous density enhancement of the pre and post-septal segment, with extension into the soft intra and extraconal tissues, promoting secondary proptosis without developing a definite mass; such inflammatory changes extend into the supraorbital, palpebral and malar region, with no evidence of organized fluid collections.

asite cleanse, switch to oral administration with prednisone 1 mg/kg/day. The clinical evolution of the patient improved and tolerance was adequate.

Finally, the patient was discharged with a regimen based on cyclophosphamide 750 mg/month for 6 months, steroids 1 mg/kg/day until further notice, and prophylactic trimetho-




Fig. 3 – Histopathological study. Upper: H&E stain. Lower: Masson trichrome stain. (A) General view: connective and adipose tissue with abundant acute and chronic inflammatory infiltrate (lymphocytes and polymorphic nuclear neutrophils) forming stem centers, with con eosinophilia and focal necrosis. (B-F) Granulomatous reaction with giant cells and the presence of vasculitis of the muscle arteriolar vessels (red arrow) and venules (blue arrow), due to hyperplasia of the vascular walls, vascular occlusion and fibrinoid necrosis (black arrow).

prim/sulfamethoxazole 160 mg/800 mg Monday, Wednesday and Friday.

Currently, because of insurance authorization delays, the patient has been unable to complete her treatment and hence the response has been partial, with persistent proptosis and compromised visual acuity.

Discussion

GPA is a small vessel vasculitis associated with the presence of antineutrophil cytoplasmic antibodies⁷; however, their positivity is not essential for a clinical diagnosis. This disease is mainly characterized by compromised upper and lower respiratory tract, associated with renal manifestations.⁷ It should be highlighted that the literature describes the isolated involvement of other anatomic structures, such as the orbit, which was the principal manifestation in this particular patient, in whom the diagnosis was established based on the criteria of the American College of Rheumatology,⁷ in the light of the findings of the biopsy and the purulent nasal discharge.

With regards to the ocular involvement, it is estimated to range between 14 and 60% of the patients diagnosed with GPA, mainly necrotizing nodular episcleritis, scleritis, corneal ulcers and retinal vasculitis⁴; the orbital manifestations are present in 45–60% of the patients with the disease,⁶ and it is estimated to be the primary target, prior to the development of systemic manifestations.^{6,8} In more than 10% of the patients with this isolated involvement, the antineutrophil cytoplasmic antibodies result negative,⁹ as is actually this case.

The presentation of the retroorbital granulomatous pseudotumor is usually unilateral and compromises the intra- and extraconal space; only 5% of the masses are limited to the intraconal space,¹⁰ meaning due to a primary or secondary origin after the underlying sinus inflammation.⁴ GPA with orbital involvement is clinically expressed as proptosis and the subsequent mechanical compression leading to atrophy of the optic nerve and blindness in 17% of the cases¹¹; enophthalmos, in the late phase of the pseudotumor due to contracture of the orbital cavity^{6,10}; epiphora, due to obstruction of the nasolacrimal ducts and infiltration of the lacrimal gland (dacyroadenitis); diplopia, due to direct compression of the eye globe, infiltration of the extraocular muscles, vasculitis that compromises the *vasa vasorum* of the extraocular muscles; ophthalmoplegia dolorosa, due to cranial nerve involvement (Tolossa-Hunt syndrome).^{6,10} The concomitant involvement of both branches of the VIII nerve – auditory and vestibular – is striking, due to a left otomastoiditis which was the culprit of the left ear neurosensory hearing loss and of the subjective vertigo.

In contrast to the literature review,¹²⁻⁴⁵ all of these manifestations were present in the case reports and case series; of the 67 patients diagnosed with GPA and some kind of ocular involvement, 63 had orbital disease, around 25 patients had paranasal sinus involvement or clinical manifestations of sinusitis. The most frequent ocular symptoms and findings were impaired visual acuity, diplopia, proptosis, and extraocular movement limitations. The common denominator for treatment was cyclophosphamide, oral methylprednisolone pulses, methotrexate or azathioprine; in 25 patients their ocular symptoms improved without relapses, 10 patients were

refractory to treatment and 9 of them required management with rituximab and 1 with infliximab; at least 6 experienced progressive visual acuity decline and finally became blind, around 7 underwent orbital decompression due to severe pain and significant visual acuity impairment, 2 required enucleation, one due to severe ocular pain and the second one due to non-response to corticoids or radiotherapy. With regards to gender, women were more affected.

With regards to the development of vasculitis and paranasal sinus-related periorbital cellulitis,¹¹ these two may co-exist, as it was the case with this patient; this explains the periods of partial improvement with antibiotic therapy administered on several occasions. Nevertheless, considering the natural history of the underlying disease, it is necessary to add immunosuppressive therapy¹¹ and cytotoxic agents (cyclophosphamide, azathioprine or methotrexate)⁶ to modulate the immune system. In case of relapse or refractory response to treatment, second line biologic therapy shall be required such as rituximab or infliximab.⁴⁵ In terms of severe cases compromising the orbit and adjacent structures, ENT and ophthalmology shall be required to perform orbital decompression,⁹ in order to lower the risk of optic nerve ischemia and progression to blindness.

In this case, not all the differential diagnoses could be ruled out, but just the most frequent ones such as thyroid disease and infectious processes; this is a common pattern in all case reports. In this regard, the physician must keep in mind IgG4-related disease, thyroid disease (thyroid orbitopathy or Graves' disease), sarcoidosis, temporal arteritis, polyarteritis nodosa, Kawasaki, histiocytosis, xanthogranuloma, cavernous hemangioma, lymphatic venous malformations, infection (post-septal cellulitis, mycobacteria infection, invasive fungal sinusitis due to *Mucor* or *Aspergillus* sp.), neoplastic processes such as lymphoma (predominantly B cells) and metastatic disease.^{6,8,10}

Conclusion

On the basis of this clinical case, one may conclude that sound communication and doctor-patient relationship is essential, in addition to adequate communication among the healthcare practitioners for interdisciplinary management. Remember the importance of a detailed medical history and comprehensive physical examination, since any upper and lower respiratory tract disease-associated proptosis, or renal involvement as an isolated manifestation, represents a diagnostic aid for suspicious GPA, without ruling out the pathology, notwithstanding the non-positive antineutrophil cytoplasmic antibodies. Additionally, the clinician should be aware of the direct impact of a compromised orbit on optic nerve ischemia and the subsequent irreversible blindness, if timely intervention is not offered.

Patient perception

During the ophthalmology clinical interview, the patient and her relative expressed their concern over the recurrence of the clinical situation, despite the multiplicity of treatments received. They also expressed their uncertainty about the

long-term visual prognosis, since that could affect her daily life performance.

Funding

None declared.

Conflict of interests

The authors have no conflict of interests to disclose.

REFERENCES

1. Falk RJ, Gross WL, Guillevin L, Hoffman GS, Jayne DRW, Jennette JC, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. *Arthritis Rheum.* 2011;63:863-4, <http://dx.doi.org/10.1002/art.30286>.
2. Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. *Clin Exp Nephrol.* 2013;17:603-6, <http://dx.doi.org/10.1007/s10157-013-0869-6>.
3. Bullen CL, Liesegang TJ, McDonald TJ, DeRemee RA. Ocular complications of Wegener's granulomatosis. *Ophthalmology.* 1983;90:279-90, [http://dx.doi.org/10.1016/S0016-6420\(83\)34574-7](http://dx.doi.org/10.1016/S0016-6420(83)34574-7).
4. Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. *Autoimmun Rev.* 2014;13:1121-5, <http://dx.doi.org/10.1016/j.autrev.2014.08.017>.
5. Papaliolis GN. Ophthalmologic manifestations of systemic vasculitis. *Curr Opin Ophthalmol.* 2017;28:613-6, <http://dx.doi.org/10.1097/ICU.0000000000000422>.
6. Karra Muller JHL. Orbital granulomatosis with polyangiitis (Wegener granulomatosis). NIH Public Access. 2014;138:1110-4, <http://dx.doi.org/10.5858/arpa.2013-0006-RS>.
7. Lutalo PM, D'Cruz DP. Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener's granulomatosis). *J Autoimmun.* 2014;48-49:94-8, <http://dx.doi.org/10.1016/j.jaut.2014.01.028>.
8. Rosenbaum JT, Choi D, Wilson DJ, Grossniklaus HE, Harrington CA, Sibley CH, et al. Orbital pseudotumor can be a localized form of granulomatosis with polyangiitis as revealed by gene expression profiling. *Exp Mol Pathol.* 2016;99:271-8, <http://dx.doi.org/10.1016/j.yexmp.2015.07.002>.
9. Kubaisi B, Samra KA, Foster CS. Granulomatosis with polyangiitis (Wegener's disease): an updated review of ocular disease manifestations. *Intractable Rare Dis Res.* 2016;5:61-9, <http://dx.doi.org/10.5582/irdr.2016.01014>.
10. Pakalniskis MG, Berg AD, Policeni BA, Gentry LR, Sato Y, Moritani T, et al. The many faces of granulomatosis with polyangiitis: a review of the head and neck imaging manifestations. *Am J Roentgenol.* 2015;205:W619-29, <http://dx.doi.org/10.2214/AJR.14.13864>.
11. Kubal AA, Perez VL. Ocular manifestations of ANCA-associated vasculitis. *Rheum Dis Clin North Am.* 2010;36:573-86, <http://dx.doi.org/10.1016/j.rdc.2010.05.005>.
12. Bambery P, Gupta A, Sakhija V, Kaur U, Gangwar DN, Jain IS, et al. Ocular manifestations of Wegener's granulomatosis in north India. *Sarcoidosis.* 1988;5:132-5.
13. Beji S, Fatma LB, Chebbi A, Rais L, Krid M, Smaoui W, et al. A case of exorbitism in association with Wegener's granulomatosis with renal involvement. *Saudi J Kidney Dis Transpl.* 2012;23:330-3.

14. Hisahara S, Yamada M, Matsuura Y, Tsuda E, Akiyama Y, Saitoh M, et al. ANCA-negative granulomatosis with polyangiitis presenting with orbital apex syndrome and recurrent pachymeningitis: a case report. *J Neurol Sci.* 2016;368:175-7, <http://dx.doi.org/10.1016/j.jns.2016.07.013>.
15. Kaufmann J, Schulze E, Voigt U, Strobel J, Hein G, Stein G. Orbital inflammatory pseudotumor due to hypersensitivity vasculitis and mononeuritis multiplex in a patient with atypical, cANCA-positive Wegener's granulomatosis. *Rheumatol Int.* 2003;23:138-42, <http://dx.doi.org/10.1007/s00296-002-0236-5>.
16. Kopstein AB, Kristopaitis T, Gujrati TM, Blake KA, Bouchard CS. Orbital Wegener granulomatosis without systemic findings. *Ophthal Plast Reconstr Surg.* 1999;15:467-9.
17. Krzystolik Z, Fiedorowicz-Fabrycy I, Karczewicz D. Ocular symptoms in Wegener's granulomatosis – personal observations. *Klin Oczna.* 1993;95:183-6.
18. Kubota T, Hirose H. Ocular changes in a limited form of Wegener's granulomatosis: patient with cutaneous ulcer of upper eyelid. *Jpn J Ophthalmol.* 2003;47:398-400.
19. Kutzbach BR, Kashiwagi DT, Couch SM, Burton MC. Diagnosis: the eyes have it. *Am J Med.* 2010;123:e1-2, <http://dx.doi.org/10.1016/j.amjmed.2009.12.039>.
20. Lahoz Zamarro MT, Martínez Subías J, Martínez Sanz G. Unusual presentation forms of Wegener's disease. *Acta Otorrinolaringol Esp.* 2003;54:102-6.
21. Lopes Caçola R, Morais SA, Carvalho R, Môco R. Bilateral dacryoadenitis as initial presentation of a locally aggressive and unresponsive limited form of orbital granulomatosis with polyangiitis. *BMJ Case Rep.* 2016, <http://dx.doi.org/10.1136/bcr-2015-214099>.
22. Louati H, Chebbi A, Ben Hassen I, Douira W, Ben Hassine L, Lahmar L, et al. Granulomatose de Wegener révélée par une localisation orbito-méningée: à propos d'un cas. *J Fr Ophthalmol.* 2012;35:622.e1-4, <http://dx.doi.org/10.1016/j.jfo.2012.04.006>.
23. Molina-Sócola FE, Galván-Carrasco MP, del Estad-Cabello A, Sánchez-Vicente JL, Contreras-Díaz M, Rueda-Rueda T. Tumорación orbitaria por extensión rinosinusal en un paciente con granulomatosis de Wegener. *Arch Soc Esp Oftalmol [Internet].* 2016;91:442-5, <http://dx.doi.org/10.1016/j.joftal.2016.02.011>.
24. Bertagna F, Treglia G, Rossini P, Giubbini R. An unusual orbital localization of Wegener granulomatosis detected by 18F-FDG PET/CT. *Clin Nucl Med.* 2014;39:711-2, <http://dx.doi.org/10.1097/RLU.0b013e31829b9e82>.
25. Ogasawara T, Kasamatsu N, Haga T, Kobayashi T, Shibata M, Hashizume I. A case of Wegener's granulomatosis with orbital inflammatory pseudotumor. *Nihon Kokyuki Gakkai Zasshi.* 2009;47:308-13.
26. Ooka S, Maeda A, Ito H, Omata M, Yamada H, Ozaki S. Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener's granulomatosis: a case report. *Mod Rheumatol.* 2009;19:80-3, <http://dx.doi.org/10.1007/s10165-008-0119-z>.
27. Ostri C, Heegaard S, Prause JU. Sclerosing Wegener's granulomatosis in the orbit. *Acta Ophthalmol.* 2008;86:917-20, <http://dx.doi.org/10.1111/j.1755-3768.2008.01179.x>.
28. Pinto Bonilla JC, Lanuza García A, Hernández Galilea E, Günes G, Arias López MC. Orbital manifestation of Wegener's granulomatosis. *Arch Soc Esp Oftalmol.* 2004;79:243-6.
29. Siddiqui S, Kinshuck AJ, Srinivasan VR. Orbital apex syndrome secondary to granulomatosis with polyangiitis. *BMJ Case Rep.* 2013, <http://dx.doi.org/10.1136/bcr-2013-009519>.
30. Singh M, Singh U, Zadeng Z. Orbital presentation of systemic vasculitis: a diagnostic and management challenge. *Nepal J Ophthalmol.* 2015;7:65, <http://dx.doi.org/10.3126/nepjoph.v7i1.13173>.
31. Sonawale A, Rajadhyaksha A, Mangalgi S. Oculo-otological manifestations in a case of granulomatosis with polyangiitis. *J Assoc Physicians India.* 2017;65:84.
32. Tachfouti S, Boutimzine N, Cherkaoui O, Bencherif Z, Dahreddine Mohcine Z. Revealing dacryoadenitis inflammation as Wegener's granulomatosis. *Bull Soc Belge Ophthalmol.* 2005;296:7-12.
33. Thawley SE. Wegener's granulomatosis: unusual indication for orbital decompression. *Laryngoscope.* 1979;89:145-54.
34. Tsironi E, Eftaxias B, Karabatas CH, Ioachim E, Kalogeropoulos C, Psilas K. An unusually longstanding, strictly ocular, limited form of Wegener's granulomatosis. *Acta Ophthalmol Scand.* 2004;83:123-5, <http://dx.doi.org/10.1111/j.1600-0420.2004.00333.x>.
35. Boefert P, Boefert A, Haxel B. Unklarer tumor der orbita. *Laryngo-Rhino-Otologie.* 2016;95:346-8, <http://dx.doi.org/10.1055/s-0042-102656>.
36. Vanwynsberghe D, van den Broecke C, Bauters W, Decock C. Ocular presentation of Wegener granulomatosis. *Bull Soc Belge Ophthalmol.* 2007;303:7-11.
37. Vischio JA, McCrary CT. Orbital Wegener's granulomatosis: a case report and review of the literature. *Clin Rheumatol.* 2008;27:1333-6, <http://dx.doi.org/10.1007/s10067-008-0949-2>.
38. Yamashita K, Kobayashi S, Kondo M, Ishikura H, Shibuya Y, Hayasaka S. Elevated anti-neutrophil cytoplasmic antibody titer in a patient with atypical orbital pseudotumor. *Ophthalmologica.* 1995;209:172-5, <http://dx.doi.org/10.1159/000310606>.
39. Campello I, Sanjuán F, Brieva L, Losfáblos F, Hermida I, Velilla J. Exophthalmos and cranial neuropathy as a form of presentation of Wegener's granulomatosis. *Neurologia.* 1997;12:168-71.
40. Cassan SM, Divertie MB, Hollenhorst RW, Harrison EG. Pseudotumor of the orbit and limited Wegener's granulomatosis. *Ann Intern Med.* 1970;72:687-93.
41. Duncker G, Nölle B, Asmus R, Koltze H, Rochels R. Orbital involvement in Wegener's granulomatosis. *Adv Exp Med Biol.* 1993;336:315-7.
42. Fadil H, González-Toledo E, Kelley RE, Henley J. Wegener's granulomatosis with extension to the cavernous sinus. *J La State Med Soc.* 2007;159:212-4.
43. Haynes BF, Fishman ML, Fauci AS, Wolff SM. The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and review of the literature. *Am J Med.* 1977;63:131-41.
44. Hibino M, Kondo T. Dacryoadenitis with ptosis and diplopia as the initial presentation of granulomatosis with polyangiitis. *Intern Med.* 2017;56:2649-53, <http://dx.doi.org/10.2169/internalmedicine.8761-16>.
45. Raffray L, Guillevin L. Treatment of eosinophilic granulomatosis with polyangiitis: a review. *Drugs.* 2018;78:809-21, <http://dx.doi.org/10.1007/s40265-018-0920-8>.